A Systemically-Administered Small Molecule Antagonist of CCR9 Acts as a Tissue-Selective Inhibitor of Lymphocyte Trafficking

A goal for developers of immunomodulatory drugs has long been a systemically administered small molecule that can selectively inhibit inflammation in specific tissues. The chemokine receptor CCR9 is an attractive target for this approach, as entry of T cells into the small intestine from blood requi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tubo, Noah J., Wurbel, Marc A., Charvat, Trevor T., Schall, Thomas J., Walters, Matthew J., Campbell, James J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510197/
https://www.ncbi.nlm.nih.gov/pubmed/23209760
http://dx.doi.org/10.1371/journal.pone.0050498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510197/
https://www.ncbi.nlm.nih.gov/pubmed/23209760
http://dx.doi.org/10.1371/journal.pone.0050498

Ejemplares similares